Business Description
Roquefort Therapeutics PLC
ISIN : GB00BMDQ2T15
Description
Roquefort Therapeutics PLC is engaged in pursuing opportunities to acquire medical biotechnology businesses that are at an early stage in the medical sector including Drug and vaccine development; Diagnostics; Immuno-therapy; and Cell and gene therapies. The principal activity of the Company is to develop pre-clinical next generation medicines focused on hard to treat cancers.
Financial Strength
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | No Debt | |||||
| Equity-to-Asset | 0.9 | |||||
| Interest Coverage | No Debt | |||||
| Piotroski F-Score | 5/9 | |||||
| Altman Z-Score | 3.86 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History |
|---|
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 20.46 | |||||
| 9-Day RSI | 23.39 | |||||
| 14-Day RSI | 24.62 | |||||
| 6-1 Month Momentum % | 3.7 | |||||
| 12-1 Month Momentum % | 3.7 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 2.26 | |||||
| Quick Ratio | 2.26 | |||||
| Cash Ratio | 1.75 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History |
|---|
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Operating Margin % | -967 | |||||
| Net Margin % | -872 | |||||
| FCF Margin % | -894 | |||||
| ROE % | -27.28 | |||||
| ROA % | -24.94 | |||||
| ROIC % | -31.55 | |||||
| ROC (Joel Greenblatt) % | -3751.46 | |||||
| ROCE % | -28.95 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 22 | |||||
| PB Ratio | 1.1 | |||||
| EV-to-EBIT | -2.66 | |||||
| EV-to-EBITDA | -2.67 | |||||
| EV-to-Revenue | 25.73 | |||||
| EV-to-FCF | -2.88 | |||||
| Earnings Yield (Greenblatt) % | -37.59 | |||||
| FCF Yield % | -31.46 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Roquefort Therapeutics PLC Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil £) | 0.2 | ||
| EPS (TTM) (£) | -0.013 | ||
| Beta | -0.22 | ||
| Volatility % | 35.29 | ||
| 14-Day RSI | 24.62 | ||
| 14-Day ATR (£) | 0.002849 | ||
| 20-Day SMA (£) | 0.045575 | ||
| 12-1 Month Momentum % | 3.7 | ||
| 52-Week Range (£) | 0.0385 - 0.095 | ||
| Shares Outstanding (Mil) | 129.15 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 5 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Roquefort Therapeutics PLC Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Roquefort Therapeutics PLC Stock Events
| Event | Date | Price(£) | ||
|---|---|---|---|---|
| No Event Data | ||||
Roquefort Therapeutics PLC Frequently Asked Questions
What is Roquefort Therapeutics PLC(LSE:ROQ)'s stock price today?
The current price of LSE:ROQ is £0.04. The 52 week high of LSE:ROQ is £0.10 and 52 week low is £0.04.
When is next earnings date of Roquefort Therapeutics PLC(LSE:ROQ)?
The next earnings date of Roquefort Therapeutics PLC(LSE:ROQ) is 2024-09-27 Est..
Does Roquefort Therapeutics PLC(LSE:ROQ) pay dividends? If so, how much?
Roquefort Therapeutics PLC(LSE:ROQ) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers